Sample Size Determination. The Fundamentals of Biostatistics in Clinical Research Workshop India, March 2007 Mario Chen
|
|
- Alaina Nash
- 7 years ago
- Views:
Transcription
1 Sample Size Determination The Fundamentals of Biostatistics in Clinical Research Workshop India, March 2007 Mario Chen
2 Framework Objectives Type of Inference: Estimation or Hypothesis Testing Study Design: Type of Study and Sample Size Data Collection Data Management Data Analysis
3 Selection of summary measure Objective Population Endpoint Individual Summary measure* Sample Parameter Population * Depends of primary analysis method
4 Sample Size for Estimation Necessary Components: 1. Indicator or summary measure of interest (proportions or means) 2. Desired Confidence Level (1-α) 3. Desired Precision Level (d) 4. Expected Variability in the study population: For means (σ) For proportions (P)
5 Sample Size for Estimation (Proportions) Example: 1. Summary measure: Prevalence of Vibrio Cholerae 2. Confidence Level: 95% 3. Precision Level: d = 3 percent points, i.e n = Variability: Estimate of P = 15% (from previous studies) Recommendation: If If there is is not a good estimate for P, use P closest to to 50% to to be conservative
6 Sample Size for Estimation (Means) Example: 1. Summary measure: Mean hydrocele size among filariasis infected patients 2. Confidence Level: 95% 3. Precision Level: d = 1.5 mm. 4. Variability: Estimate for σ = 5.7 mm. n = 58 To estimate σ we can use previous studies, expert advice, or or a pilot study
7 Sample Size for Hypothesis Testing Necessary Components: 1. Summary measure of interest (proportions or means) 2. Statistical Hypotheses 3. Significance Level (α) 4. Desired Power (1-β)
8 Sample Size for Hypothesis Testing Necessary Components (cont d): 5. Effect Size: Smallest difference worth detecting (clinically)
9 What is a clinically important difference to detect? Standard drug has 75% Cure rate And New treatment... 76%?... 77%?... 78%?... 79%? 87%?... 88%?... 89%... 90%?
10 Cured rate for the New Treatment? Ridiculous notion... How would I know this I m doing the study to estimate the effect. I have no data on which to base an estimate True, but You do not estimate the cure rate for the new treatment! You determine the cure rate reflecting the clinically important difference to detect, which may have no relation to the actual cure rate
11 Example Standard drug Cost of $30.00 for 28 days 2 oral doses per day Minimal side effects New treatment Cost of $ for 28 days A single oral dose per day Neutropenia, blurred vision, and proteinuria
12 What is a clinically important difference to detect? Standard drug has 75% Cure rate And New treatment... 76%?... 77%?... 78%?... 79%? 87%?... 88%?... 89%... 90%? We believe 15% represents a clinically important difference to detect If the difference is greater then changes will occur If the difference is smaller, groups are considered equivalent (status quo preserved)
13 Sample Size for Hypothesis Testing Necessary Components (cont d): 6. Variability expected in the population For means (σ1, σ2) For proportions (P1, P2)
14 Sample Size for Hypothesis Testing Example for proportions: 1. Summary measure: Proportion Cured 2. Statistical Hypotheses: H 0 : Proportion cured is the same with both the new treatment and the standard treatment H 1 : Proportion cured is higher with the new treatment than with the standard treatment One sided vs. two sided Alternative Hypothesis.
15 Sample Size for Hypothesis Testing (cont-d) 3. Significance Level: α = 5% 4. Power: 1-β = 90% (never lower than 80%) 5. Effect size: P 2 P 1 = 15% n = Variability: Estimate for P 1 = 75% Estimate for P 2 = 90% Recommendation: a) a) Define level for for P for for the the baseline group b) b) Use effect size to to obtain level of of P for for the the study group
16 Main Determinant of Study Size Recommendations when budget is not enough: 1. (Estimation) Lower desired precision. 2. (Hypothesis Testing) Lower desired power or increase minimum detectable effect size. 3. It is not recommended to change confidence levels, significance levels, or variance estimates. 4. If after all these changes, budget is still insufficient, one has to decide between: Not conducting the study until enough budget has been obtained, or go ahead with the study knowing that the results are likely to be inconclusive (pilot study or exploratory).
17 Adjustments to Sample Size Non-Response (and attrition): n 2 = n 1 /(1-NR) n 2 = final size, n 1 = effective size NR = Non-response (and attrition) rate
18 Other Considerations Data dependencies (e.g., Matching, Repeated Measures). Multivariate methods (e.g., control for confounding). Multiplicity issues (e.g., Multiple testing, endpoints, treatments, interim analyses). Other variables of interest (e.g., time to event). Other hypotheses (e.g., equivalence).
19 Software PASS ( nquery ( EPI-INFO ( EPIDAT (
20 What should be included in the protocol? Justification in terms of power or precision for the primary endpoint Method used to calculate the sample size should be consistent with the primary method for data analysis and appropriate for the study design Historical data to support the assumptions Justification in terms of feasibility
21 Questions?
22 Exercise: Case Scenarios Statistical Hypotheses Significance level and desired power Effect size discussion
Sample Size Planning, Calculation, and Justification
Sample Size Planning, Calculation, and Justification Theresa A Scott, MS Vanderbilt University Department of Biostatistics theresa.scott@vanderbilt.edu http://biostat.mc.vanderbilt.edu/theresascott Theresa
More informationAnalysis Issues II. Mary Foulkes, PhD Johns Hopkins University
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationTUTORIAL on ICH E9 and Other Statistical Regulatory Guidance. Session 1: ICH E9 and E10. PSI Conference, May 2011
TUTORIAL on ICH E9 and Other Statistical Regulatory Guidance Session 1: PSI Conference, May 2011 Kerry Gordon, Quintiles 1 E9, and how to locate it 2 ICH E9 Statistical Principles for Clinical Trials (Issued
More informationTesting Multiple Secondary Endpoints in Confirmatory Comparative Studies -- A Regulatory Perspective
Testing Multiple Secondary Endpoints in Confirmatory Comparative Studies -- A Regulatory Perspective Lilly Yue, Ph.D. Chief, Cardiovascular and Ophthalmic Devices Branch Division of Biostatistics CDRH/FDA
More informationWorkshop on Impact Evaluation of Public Health Programs: Introduction. NIE-SAATHII-Berkeley
Workshop on Impact Evaluation of Public Health Programs: Introduction NHRM Goals & Interventions Increase health service use and healthrelated community mobilization (ASHAs) Increase institutional deliveries
More informationStatistics in Medicine Research Lecture Series CSMC Fall 2014
Catherine Bresee, MS Senior Biostatistician Biostatistics & Bioinformatics Research Institute Statistics in Medicine Research Lecture Series CSMC Fall 2014 Overview Review concept of statistical power
More informationTwo-Sample T-Tests Assuming Equal Variance (Enter Means)
Chapter 4 Two-Sample T-Tests Assuming Equal Variance (Enter Means) Introduction This procedure provides sample size and power calculations for one- or two-sided two-sample t-tests when the variances of
More informationStudy Design and Statistical Analysis
Study Design and Statistical Analysis Anny H Xiang, PhD Department of Preventive Medicine University of Southern California Outline Designing Clinical Research Studies Statistical Data Analysis Designing
More informationTwo-Sample T-Tests Allowing Unequal Variance (Enter Difference)
Chapter 45 Two-Sample T-Tests Allowing Unequal Variance (Enter Difference) Introduction This procedure provides sample size and power calculations for one- or two-sided two-sample t-tests when no assumption
More informationFixed-Effect Versus Random-Effects Models
CHAPTER 13 Fixed-Effect Versus Random-Effects Models Introduction Definition of a summary effect Estimating the summary effect Extreme effect size in a large study or a small study Confidence interval
More informationAIE: 85-86, 193, 217-218, 294, 339-340, 341-343, 412, 437-439, 531-533, 682, 686-687 SE: : 339, 434, 437-438, 48-454, 455-458, 680, 686
Knowledge and skills. (1) The student conducts laboratory investigations and fieldwork using safe, environmentally appropriate, and ethical practices. The student is expected to: (A) demonstrate safe practices
More informationFAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE
FAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE Marion Gruber, Ph.D. Director Office of Vaccines Research & Review Center for Biologics Evaluation and Research US Food and Drug Administration
More informationHow to evaluate medications in Multiple Sclerosis when placebo controlled RCTs are not feasible
University of Florence Dept. of Neurosciences Careggi University Hospital Dept of Neurosciences How to evaluate medications in Multiple Sclerosis when placebo controlled RCTs are not feasible Luca Massacesi,
More informationHow to get accurate sample size and power with nquery Advisor R
How to get accurate sample size and power with nquery Advisor R Brian Sullivan Statistical Solutions Ltd. ASA Meeting, Chicago, March 2007 Sample Size Two group t-test χ 2 -test Survival Analysis 2 2 Crossover
More informationIS 30 THE MAGIC NUMBER? ISSUES IN SAMPLE SIZE ESTIMATION
Current Topic IS 30 THE MAGIC NUMBER? ISSUES IN SAMPLE SIZE ESTIMATION Sitanshu Sekhar Kar 1, Archana Ramalingam 2 1Assistant Professor; 2 Post- graduate, Department of Preventive and Social Medicine,
More informationSummary ID# 13614. Clinical Study Summary: Study F3Z-JE-PV06
CT Registry ID# Page 1 Summary ID# 13614 Clinical Study Summary: Study F3Z-JE-PV06 INSIGHTS; INSulin-changing study Intending to Gain patients insights into insulin treatment with patient-reported Health
More informationMind on Statistics. Chapter 12
Mind on Statistics Chapter 12 Sections 12.1 Questions 1 to 6: For each statement, determine if the statement is a typical null hypothesis (H 0 ) or alternative hypothesis (H a ). 1. There is no difference
More informationLikelihood Approaches for Trial Designs in Early Phase Oncology
Likelihood Approaches for Trial Designs in Early Phase Oncology Clinical Trials Elizabeth Garrett-Mayer, PhD Cody Chiuzan, PhD Hollings Cancer Center Department of Public Health Sciences Medical University
More informationMorris Animal Foundation
General Information: Morris Animal Foundation First Award Proposal Morris Animal Foundation (MAF) is dedicated to funding proposals that are relevant to our mission of advancing the health and well-being
More information1.0 Abstract. Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA. Keywords. Rationale and Background:
1.0 Abstract Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA Keywords Rationale and Background: This abbreviated clinical study report is based on a clinical surveillance
More informationConfidence Intervals for the Difference Between Two Means
Chapter 47 Confidence Intervals for the Difference Between Two Means Introduction This procedure calculates the sample size necessary to achieve a specified distance from the difference in sample means
More informationPower Analysis: Intermediate Course in the UCLA Statistical Consulting Series on Power
Power Analysis: Intermediate Course in the UCLA Statistical Consulting Series on Power By Jason C. Cole, PhD QualityMetric, Inc. Senior Consulting Scientist jcole@qualitymetric.com 310-539-2024 Consulting
More informationGuidance for the format and content of the protocol of non-interventional post-authorisation safety studies
26 September 2012 EMA/623947/2012 Patient Health Protection Guidance for the format and content of the protocol of non-interventional post-authorisation Introduction From 10 January 2013, marketing authorisation
More informationUniversity of Maryland School of Medicine Master of Public Health Program. Evaluation of Public Health Competencies
Semester/Year of Graduation University of Maryland School of Medicine Master of Public Health Program Evaluation of Public Health Competencies Students graduating with an MPH degree, and planning to work
More informationBiostat Methods STAT 5820/6910 Handout #6: Intro. to Clinical Trials (Matthews text)
Biostat Methods STAT 5820/6910 Handout #6: Intro. to Clinical Trials (Matthews text) Key features of RCT (randomized controlled trial) One group (treatment) receives its treatment at the same time another
More informationClinical trials for medical devices: FDA and the IDE process
Clinical trials for medical devices: FDA and the IDE process Owen Faris, Ph.D. Deputy Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health,
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationSummary and general discussion
Chapter 7 Summary and general discussion Summary and general discussion In this thesis, treatment of vitamin K antagonist-associated bleed with prothrombin complex concentrate was addressed. In this we
More informationSAMPLING & INFERENTIAL STATISTICS. Sampling is necessary to make inferences about a population.
SAMPLING & INFERENTIAL STATISTICS Sampling is necessary to make inferences about a population. SAMPLING The group that you observe or collect data from is the sample. The group that you make generalizations
More informationUniversity of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol
University of Hawai i Human Studies Program Guidelines for Developing a Clinical Research Protocol Following are guidelines for writing a clinical research protocol for submission to the University of
More informationBiostatistics: Types of Data Analysis
Biostatistics: Types of Data Analysis Theresa A Scott, MS Vanderbilt University Department of Biostatistics theresa.scott@vanderbilt.edu http://biostat.mc.vanderbilt.edu/theresascott Theresa A Scott, MS
More informationChapter 2. Hypothesis testing in one population
Chapter 2. Hypothesis testing in one population Contents Introduction, the null and alternative hypotheses Hypothesis testing process Type I and Type II errors, power Test statistic, level of significance
More informationIf several different trials are mentioned in one publication, the data of each should be extracted in a separate data extraction form.
General Remarks This template of a data extraction form is intended to help you to start developing your own data extraction form, it certainly has to be adapted to your specific question. Delete unnecessary
More informationMethodology Understanding the HIV estimates
UNAIDS July 2014 Methodology Understanding the HIV estimates Produced by the Strategic Information and Monitoring Division Notes on UNAIDS methodology Unless otherwise stated, findings in this report are
More informationClass 19: Two Way Tables, Conditional Distributions, Chi-Square (Text: Sections 2.5; 9.1)
Spring 204 Class 9: Two Way Tables, Conditional Distributions, Chi-Square (Text: Sections 2.5; 9.) Big Picture: More than Two Samples In Chapter 7: We looked at quantitative variables and compared the
More informationKADI SARVA VISHWA VIDYALAYA GANDHINAGAR. Ph.D. Course Work SOCIAL WORK
KADI SARVA VISHWA VIDYALAYA GANDHINAGAR Ph.D. Course Work In SOCIAL WORK Paper-I: Research Methodology Section-A (Common to all faculties) 1) Introduction to Research Methodology: Meaning of Research,
More informationGuidelines for AJO-DO submissions: Randomized Clinical Trials June 2015
Guidelines for AJO-DO submissions: Randomized Clinical Trials June 2015 Complete and transparent reporting allows for accurate assessment of the quality of trial and correct interpretation of the trial
More information3.4 Statistical inference for 2 populations based on two samples
3.4 Statistical inference for 2 populations based on two samples Tests for a difference between two population means The first sample will be denoted as X 1, X 2,..., X m. The second sample will be denoted
More informationUse advanced techniques for summary and visualization of complex data for exploratory analysis and presentation.
MS Biostatistics MS Biostatistics Competencies Study Development: Work collaboratively with biomedical or public health researchers and PhD biostatisticians, as necessary, to provide biostatistical expertise
More informationOrganizing Your Approach to a Data Analysis
Biost/Stat 578 B: Data Analysis Emerson, September 29, 2003 Handout #1 Organizing Your Approach to a Data Analysis The general theme should be to maximize thinking about the data analysis and to minimize
More information2 Precision-based sample size calculations
Statistics: An introduction to sample size calculations Rosie Cornish. 2006. 1 Introduction One crucial aspect of study design is deciding how big your sample should be. If you increase your sample size
More informationNon-inferiority studies: non-sense or sense?
Non-inferiority studies: non-sense or sense? Prof. Emmanuel Lesaffre Department of Biostatistics, Erasmus MC, Rotterdam, the Netherlands L-Biostat, K.U.Leuven, Leuven, Belgium 1 2 3 1. Review of study
More informationTests for Two Proportions
Chapter 200 Tests for Two Proportions Introduction This module computes power and sample size for hypothesis tests of the difference, ratio, or odds ratio of two independent proportions. The test statistics
More informationInterim Analysis in Clinical Trials
Interim Analysis in Clinical Trials Professor Bikas K Sinha [ ISI, KolkatA ] Courtesy : Dr Gajendra Viswakarma Visiting Scientist Indian Statistical Institute Tezpur Centre e-mail: sinhabikas@yahoo.com
More informationSample Size Determination in Clinical Trials HRM-733 CLass Notes
Sample Size Determination in Clinical Trials HRM-733 CLass Notes Lehana Thabane, BSc, MSc, PhD Biostatistician Center for Evaluation of Medicines St. Joseph s Heathcare 105 Main Street East, Level P1 Hamilton
More informationDefining the Beginning: The Importance of Research Design
Research and Management Techniques for the Conservation of Sea Turtles K. L. Eckert, K. A. Bjorndal, F. A. Abreu-Grobois, M. Donnelly (Editors) IUCN/SSC Marine Turtle Specialist Group Publication No. 4,
More informationHow To Check For Differences In The One Way Anova
MINITAB ASSISTANT WHITE PAPER This paper explains the research conducted by Minitab statisticians to develop the methods and data checks used in the Assistant in Minitab 17 Statistical Software. One-Way
More informationBackground paper for SAGE discussions. SAGE non-specific effects of vaccines Working Group
Evidence based recommendations on non-specific effects of BCG, DTP-containing and measles-containing vaccines on mortality in children under 5 years of age Background paper for SAGE discussions SAGE non-specific
More informationWhat does qualitative research have to offer evidence based health care? Brian Williams. Division of Community Health Sciences, University of Dundee
What does qualitative research have to offer evidence based health care? Brian Williams Division of Community Health Sciences, University of Dundee Qualitative Methods Participant observation In depth
More informationCertified in Public Health (CPH) Exam CONTENT OUTLINE
NATIONAL BOARD OF PUBLIC HEALTH EXAMINERS Certified in Public Health (CPH) Exam CONTENT OUTLINE April 2014 INTRODUCTION This document was prepared by the National Board of Public Health Examiners for the
More informationThe PCORI Methodology Report. Appendix A: Methodology Standards
The Appendix A: Methodology Standards November 2013 4 INTRODUCTION This page intentionally left blank. APPENDIX A A-1 APPENDIX A: PCORI METHODOLOGY STANDARDS Cross-Cutting Standards for PCOR 1: Standards
More informationKnowledge Objectives (2 of 2) Skills Objectives. Introduction. Process of Elimination (1 of 2) 12/20/2013
Fire Cause Determination Knowledge Objectives (1 of 2) Discuss the use of the process of elimination when determining fire cause. Explain the roles source and form of heat of ignition play in fire cause.
More informationFairfield Public Schools
Mathematics Fairfield Public Schools AP Statistics AP Statistics BOE Approved 04/08/2014 1 AP STATISTICS Critical Areas of Focus AP Statistics is a rigorous course that offers advanced students an opportunity
More informationStudy Design Sample Size Calculation & Power Analysis. RCMAR/CHIME April 21, 2014 Honghu Liu, PhD Professor University of California Los Angeles
Study Design Sample Size Calculation & Power Analysis RCMAR/CHIME April 21, 2014 Honghu Liu, PhD Professor University of California Los Angeles Contents 1. Background 2. Common Designs 3. Examples 4. Computer
More informationElements of statistics (MATH0487-1)
Elements of statistics (MATH0487-1) Prof. Dr. Dr. K. Van Steen University of Liège, Belgium December 10, 2012 Introduction to Statistics Basic Probability Revisited Sampling Exploratory Data Analysis -
More informationGuide to Biostatistics
MedPage Tools Guide to Biostatistics Study Designs Here is a compilation of important epidemiologic and common biostatistical terms used in medical research. You can use it as a reference guide when reading
More informationThe Product Review Life Cycle A Brief Overview
Stat & Quant Mthds Pharm Reg (Spring 2, 2014) Lecture 2,Week 1 1 The review process developed over a 40 year period and has been influenced by 5 Prescription User Fee Act renewals Time frames for review
More informationSnap shot. Cross-sectional surveys. FETP India
Snap shot Cross-sectional surveys FETP India Competency to be gained from this lecture Design the concept of a cross-sectional survey Key areas The concept of a survey Planning a survey Analytical cross-sectional
More informationTAKING THE GUESSWORK OUT OF FEASIBILITY ASSESSMENT IN ONCOLOGY TRIALS Data Drives Greater Predictability, Speed and Savings for Sponsors
TAKING THE GUESSWORK OUT OF FEASIBILITY ASSESSMENT IN ONCOLOGY TRIALS Data Drives Greater Predictability, Speed and Savings for Sponsors Otis Johnson, Vice President, Clinical Research Susie Kim, Associate
More informationEORTC position on the place for transparency in the clinical trials regulation
EORTC position on the place for transparency in the clinical trials regulation EORTC fully supports the need to increase transparency of clinical trials. Appropriate transparency within the clinical trials
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE STATISTICAL PRINCIPLES FOR CLINICAL TRIALS E9 Current
More information12: Analysis of Variance. Introduction
1: Analysis of Variance Introduction EDA Hypothesis Test Introduction In Chapter 8 and again in Chapter 11 we compared means from two independent groups. In this chapter we extend the procedure to consider
More informationGuidance for Industry
Guidance for Industry End-of-Phase 2A Meetings U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 Procedural Guidance
More informationThe Application of Exploratory Data Analysis (EDA) in Auditing
The Application of Exploratory Data Analysis (EDA) in Auditing Qi Liu Ph.D. Candidate (A.B.D.) Dept. of Accounting & Information Systems Rutgers University 28 th WCARS November 9, 2013 Outline Introduction
More informationClinical Study Design and Methods Terminology
Home College of Veterinary Medicine Washington State University WSU Faculty &Staff Page Page 1 of 5 John Gay, DVM PhD DACVPM AAHP FDIU VCS Clinical Epidemiology & Evidence-Based Medicine Glossary: Clinical
More information1. What is the critical value for this 95% confidence interval? CV = z.025 = invnorm(0.025) = 1.96
1 Final Review 2 Review 2.1 CI 1-propZint Scenario 1 A TV manufacturer claims in its warranty brochure that in the past not more than 10 percent of its TV sets needed any repair during the first two years
More informationImplications of dose rounding intravenous chemotherapy at a community based hospital
Implications of dose rounding intravenous chemotherapy at a community based hospital 1 2 ABSTRACT OBJECTIVES: To quantify and evaluate the total number of pharmacist interventions completed for dose rounding
More informationPerformance Excellence Process
Performance Excellence Process The Performance Excellence Process is a resultsoriented, long-term approach to the way government does business It uses several best practice methodologies, including Strategy
More informationGuidance for Industry
Guidance for Industry E9 Statistical Principles for Clinical Trials U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics
More informationDepartment/Academic Unit: Public Health Sciences Degree Program: Biostatistics Collaborative Program
Department/Academic Unit: Public Health Sciences Degree Program: Biostatistics Collaborative Program Department of Mathematics and Statistics Degree Level Expectations, Learning Outcomes, Indicators of
More informationSection 13, Part 1 ANOVA. Analysis Of Variance
Section 13, Part 1 ANOVA Analysis Of Variance Course Overview So far in this course we ve covered: Descriptive statistics Summary statistics Tables and Graphs Probability Probability Rules Probability
More informationStatistics I for QBIC. Contents and Objectives. Chapters 1 7. Revised: August 2013
Statistics I for QBIC Text Book: Biostatistics, 10 th edition, by Daniel & Cross Contents and Objectives Chapters 1 7 Revised: August 2013 Chapter 1: Nature of Statistics (sections 1.1-1.6) Objectives
More information1. FORMULATING A RESEARCH QUESTION
W R I T I N G A R E S E A R C H G R A N T P R O P O S A L 1. FORMULATING A RESEARCH QUESTION 1.1. Identify a broad area of interest through literature searches, discussions with colleagues, policy makers
More informationPlanning sample size for randomized evaluations
TRANSLATING RESEARCH INTO ACTION Planning sample size for randomized evaluations Simone Schaner Dartmouth College povertyactionlab.org 1 Course Overview Why evaluate? What is evaluation? Outcomes, indicators
More informationStandard Deviation Estimator
CSS.com Chapter 905 Standard Deviation Estimator Introduction Even though it is not of primary interest, an estimate of the standard deviation (SD) is needed when calculating the power or sample size of
More informationJames E. Bartlett, II is Assistant Professor, Department of Business Education and Office Administration, Ball State University, Muncie, Indiana.
Organizational Research: Determining Appropriate Sample Size in Survey Research James E. Bartlett, II Joe W. Kotrlik Chadwick C. Higgins The determination of sample size is a common task for many organizational
More informationExperimental Design. Power and Sample Size Determination. Proportions. Proportions. Confidence Interval for p. The Binomial Test
Experimental Design Power and Sample Size Determination Bret Hanlon and Bret Larget Department of Statistics University of Wisconsin Madison November 3 8, 2011 To this point in the semester, we have largely
More informationMeasurement in ediscovery
Measurement in ediscovery A Technical White Paper Herbert Roitblat, Ph.D. CTO, Chief Scientist Measurement in ediscovery From an information-science perspective, ediscovery is about separating the responsive
More informationSponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,
More informationComment of Consumer Reports Regarding Draft Guidance for Industry: Arsenic In Apple Juice Action Level Docket No. FDA-2012-D-0322
November 12, 2013 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, MD 20852. Comment of Consumer Reports Regarding Draft Guidance for Industry:
More informationPriority Program Translational Oncology Applicants' Guidelines
Stiftung Deutsche Krebshilfe Dr. h.c. Fritz Pleitgen Präsident Spendenkonto Kreissparkasse Köln IBAN DE65 3705 0299 0000 9191 91 BIC COKSDE33XXX Priority Program Translational Oncology Applicants' Guidelines
More informationComparing Two Groups. Standard Error of ȳ 1 ȳ 2. Setting. Two Independent Samples
Comparing Two Groups Chapter 7 describes two ways to compare two populations on the basis of independent samples: a confidence interval for the difference in population means and a hypothesis test. The
More informationProduct: Tazarotene, cream, 500 micrograms per g (0.05%) and 1.0 mg per g (0.1%), 30 g, Zorac
PUBLIC SUMMARY DOCUMENT Product: Tazarotene, cream, 500 micrograms per g (0.05%) and 1.0 mg per g (0.1%), 30 g, Zorac Sponsor: Genepharm Australasia Ltd Date of PBAC Consideration: July 2007 1. Purpose
More informationNon-Parametric Tests (I)
Lecture 5: Non-Parametric Tests (I) KimHuat LIM lim@stats.ox.ac.uk http://www.stats.ox.ac.uk/~lim/teaching.html Slide 1 5.1 Outline (i) Overview of Distribution-Free Tests (ii) Median Test for Two Independent
More informationData Analysis, Research Study Design and the IRB
Minding the p-values p and Quartiles: Data Analysis, Research Study Design and the IRB Don Allensworth-Davies, MSc Research Manager, Data Coordinating Center Boston University School of Public Health IRB
More informationEnterprise RIM: Building the Business Case. Steve Gens. Bethesda Maryland: February 25, 2014. Managing Partner Gens and Associates, Inc.
Enterprise RIM: Building the Business Case Bethesda Maryland: February 25, 2014 Steve Gens Managing Partner Gens and Associates, Inc. Disclaimer The views and opinions expressed in the following PowerPoint
More informationScottish Medicines Consortium
Scottish Medicines Consortium peginterferon alfa-2a, 135 microgram/ml and 180 microgram/ml pre-filled injections of solution for subcutaneous injection (Pegasys ) No. (561/09) Roche Products Limited 10
More informationCHAPTER 8 Planning and Budgeting
Copyright 2008 by the Foundation of the American College of Healthcare Executives 6/8/07 Version 8-1 CHAPTER 8 Planning and Budgeting The planning process Budget types Statistics budget Revenue budget
More informationPharmacy Service Initiation: Steps for New Clinical Pharmacy Leaders. Professional Practice Advisory Group
Pharmacy Service Initiation: Steps for New Clinical Pharmacy Leaders Professional Practice Advisory Group 1 Objectives Define clinical leadership Identify qualities of clinical pharmacy leaders List challenges
More informationThe Cox Proportional Hazards Model
The Cox Proportional Hazards Model Mario Chen, PhD Advanced Biostatistics and RCT Workshop Office of AIDS Research, NIH ICSSC, FHI Goa, India, September 2009 1 The Model h i (t)=h 0 (t)exp(z i ), Z i =
More informationGuidance for Industry
Guidance for Industry Adaptive Design Clinical Trials for Drugs and Biologics DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this
More informationStudy Design. Date: March 11, 2003 Reviewer: Jawahar Tiwari, Ph.D. Ellis Unger, M.D. Ghanshyam Gupta, Ph.D. Chief, Therapeutics Evaluation Branch
BLA: STN 103471 Betaseron (Interferon β-1b) for the treatment of secondary progressive multiple sclerosis. Submission dated June 29, 1998. Chiron Corp. Date: March 11, 2003 Reviewer: Jawahar Tiwari, Ph.D.
More informationEstimation following a phase II/III clinical trial
Estimation following a phase II/III clinical trial Sue Todd Department of Mathematics and Statistics University of Reading joint work with Peter Kimani and Nigel Stallard Warwick Medical School Cambridge
More informationConfidence Intervals for One Standard Deviation Using Standard Deviation
Chapter 640 Confidence Intervals for One Standard Deviation Using Standard Deviation Introduction This routine calculates the sample size necessary to achieve a specified interval width or distance from
More informationMary B Codd. MD, MPH, PhD, FFPHMI UCD School of Public Health, Physiotherapy & Pop. Sciences
HRB / CSTAR Grant Applications Training Day Convention Centre Dublin, 9 th September 2010 Key Elements of a Research Protocol Mary B Codd. MD, MPH, PhD, FFPHMI UCD School of Public Health, Physiotherapy
More informationEndpoint Selection in Phase II Oncology trials
Endpoint Selection in Phase II Oncology trials Anastasia Ivanova Department of Biostatistics UNC at Chapel Hill aivanova@bios.unc.edu Primary endpoints in Phase II trials Recently looked at journal articles
More informationFollowing are detailed competencies which are addressed to various extents in coursework, field training and the integrative project.
MPH Epidemiology Following are detailed competencies which are addressed to various extents in coursework, field training and the integrative project. Biostatistics Describe the roles biostatistics serves
More informationChapter 1: The Nature of Probability and Statistics
Chapter 1: The Nature of Probability and Statistics Learning Objectives Upon successful completion of Chapter 1, you will have applicable knowledge of the following concepts: Statistics: An Overview and
More information